Hikma Pharmaceuticals PLC (LON:HIK) Stock Has Average Target Price of GBX 2,085.83

Hikma Pharmaceuticals PLC (LON:HIK) has been assigned a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the last year is GBX 2,085.83.

A number of research analysts have weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,025 price target on shares of Hikma Pharmaceuticals in a research note on Friday, September 25th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Citigroup boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Berenberg Bank upped their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research note on Tuesday, August 11th.

Insider Buying and Selling at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler purchased 7,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Price Performance

Shares of HIK opened at GBX 1,580 on Tuesday. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. The stock has a 50 day simple moving average of GBX 1,606.66 and a 200 day simple moving average of GBX 1,489.58. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 1,865. The firm has a market capitalization of £3.27 billion, a PE ratio of 8.98, a P/E/G ratio of 2.38 and a beta of 0.66.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.